[Comparative study between verapamil and adenosine triphosphate in the treatment of paroxysmal supraventricular tachycardia].
OBJECTIVE
To evaluate the efficacy and safety of intravenous (IV) adenosine-triphosphate (ATP) and verapamil to convert acute episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm.


METHODS
Fifty patients with PSVT were randomized in two groups: A) 25 treated with IV bolus of ATP (10 or 20mg), and V) 25 treated with IV verapamil, up to 15mg, during 3min. We evaluated the time delay necessary to convert the arrhytmia, doses, and side-effects. Patients with acute ischemic syndromes (< 3 weeks), severe congestive heart failure, and treatment with dipyridamole or methylxanthine were excluded.


RESULTS
There were no differences between the two groups regarding to age, sex, and success rate. The average time till reversal were respectively, 30s and 248s for ATP and verapamil. Ventricular ectopy and general discomfort were observed in 33% of patients receiving ATP, whereas no side-effects occurred in group V.


CONCLUSIONS
ATP is a good option to convert rapidly PSVT to sinus rhythm and, probably, could be the first choice to treat PSVT patients with ventricular dysfunction.
Ferreira
J F
JF
Instituto do Coração do Hospital das Clínicas-FMUSP, São Paulo.
Pamplona
D
D
César
L A
LA
Leite
P F
PF
Sosa
E A
EA
da Luz
P L
PL
Bellotti
G
G
D000255:Adenosine Triphosphate / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D013614:Tachycardia, Paroxysmal / Q000188:drug therapy*; D014700:Verapamil / Q000008:administration & dosage / Q000627:therapeutic use*
D000255:Adenosine Triphosphate; D014700:Verapamil
Estudo comparativo entre verapamil e adenosina-trifosfato no tratamento das taquicardias paroxísticas supraventriculares.